Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy
Pregnancy is associated with an increased risk of venous thromboembolism (VTE). Previous VTE and severe thrombophilia are important risk factors. Our case was a 36-year-old woman, gravida 6, para 0, with antithrombin (AT) deficiency caused by a homozygous mutation in the heparin-binding site (HBS)....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2021/4393821 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560531912785920 |
|---|---|
| author | Hilde Fiskvik Anne F. Jacobsen Nina Iversen Carola E. Henriksson Eva-Marie Jacobsen |
| author_facet | Hilde Fiskvik Anne F. Jacobsen Nina Iversen Carola E. Henriksson Eva-Marie Jacobsen |
| author_sort | Hilde Fiskvik |
| collection | DOAJ |
| description | Pregnancy is associated with an increased risk of venous thromboembolism (VTE). Previous VTE and severe thrombophilia are important risk factors. Our case was a 36-year-old woman, gravida 6, para 0, with antithrombin (AT) deficiency caused by a homozygous mutation in the heparin-binding site (HBS). Her history included seven prior VTEs, three early and two late pregnancy losses. She was prophylactically treated with both human plasma-derived AT concentrate (hpATC) and low molecular weight heparin (LMWH), resulting in a successful 6th pregnancy and a healthy live born baby. There is limited evidence and guidance on the management of AT deficiency in pregnancy. Dosing and monitoring of anticoagulants, alone or together with hpATC, must be based on individual risk assessment. The severity of clinical manifestations varies with the type of AT deficiency. Characterization of the AT mutation may aid in the decision-making process and optimize pregnancy outcomes. |
| format | Article |
| id | doaj-art-7e55ef0be70a481d98aa98cef6492853 |
| institution | Kabale University |
| issn | 2090-6684 2090-6692 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj-art-7e55ef0be70a481d98aa98cef64928532025-02-03T01:27:24ZengWileyCase Reports in Obstetrics and Gynecology2090-66842090-66922021-01-01202110.1155/2021/43938214393821Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in PregnancyHilde Fiskvik0Anne F. Jacobsen1Nina Iversen2Carola E. Henriksson3Eva-Marie Jacobsen4Department of Hematology, Oslo University Hospital, Oslo, NorwayDepartment of Obstetrics and Gynecology, Oslo University Hospital, Oslo, NorwayDepartment of Medical Genetics, Oslo University Hospital, Oslo, NorwayInstitute of Clinical Medicine, University of Oslo, NorwayDepartment of Hematology, Oslo University Hospital, Oslo, NorwayPregnancy is associated with an increased risk of venous thromboembolism (VTE). Previous VTE and severe thrombophilia are important risk factors. Our case was a 36-year-old woman, gravida 6, para 0, with antithrombin (AT) deficiency caused by a homozygous mutation in the heparin-binding site (HBS). Her history included seven prior VTEs, three early and two late pregnancy losses. She was prophylactically treated with both human plasma-derived AT concentrate (hpATC) and low molecular weight heparin (LMWH), resulting in a successful 6th pregnancy and a healthy live born baby. There is limited evidence and guidance on the management of AT deficiency in pregnancy. Dosing and monitoring of anticoagulants, alone or together with hpATC, must be based on individual risk assessment. The severity of clinical manifestations varies with the type of AT deficiency. Characterization of the AT mutation may aid in the decision-making process and optimize pregnancy outcomes.http://dx.doi.org/10.1155/2021/4393821 |
| spellingShingle | Hilde Fiskvik Anne F. Jacobsen Nina Iversen Carola E. Henriksson Eva-Marie Jacobsen Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy Case Reports in Obstetrics and Gynecology |
| title | Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy |
| title_full | Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy |
| title_fullStr | Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy |
| title_full_unstemmed | Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy |
| title_short | Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy |
| title_sort | treatment of homozygous type ii antithrombin heparin binding site deficiency in pregnancy |
| url | http://dx.doi.org/10.1155/2021/4393821 |
| work_keys_str_mv | AT hildefiskvik treatmentofhomozygoustypeiiantithrombinheparinbindingsitedeficiencyinpregnancy AT annefjacobsen treatmentofhomozygoustypeiiantithrombinheparinbindingsitedeficiencyinpregnancy AT ninaiversen treatmentofhomozygoustypeiiantithrombinheparinbindingsitedeficiencyinpregnancy AT carolaehenriksson treatmentofhomozygoustypeiiantithrombinheparinbindingsitedeficiencyinpregnancy AT evamariejacobsen treatmentofhomozygoustypeiiantithrombinheparinbindingsitedeficiencyinpregnancy |